Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer
LONDON & SEATTLE--(BUSINESS WIRE)-- Tenpoint Therapeutics, Ltd. ('Tenpoint'), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced the appointment of Melissa Epperly as Chief Financial Officer (CFO). In this role, Epperly will oversee Tenpoint's financial strategy, capital markets activities, and operational finance functions as the company prepares for the potential U.S. launch of BRIMOCHOL™ PF, its lead candidate for the treatment of presbyopia.
'Melissa brings the vision, energy, and financial firepower we need as we prepare for the launch of BRIMOCHOL™ PF into global markets.'
Share
Epperly brings over two decades of financial leadership experience in the biopharmaceutical industry, having served as CFO for both public and private companies. Most recently, she was CFO at Zentalis Pharmaceuticals, where she led the company through a successful IPO and subsequent financings, raising over $1.25 billion. Her prior roles include CFO positions at PsiOxus Therapeutics and R-Pharm US, as well as strategic and financial roles at Anchorage Capital, Goldman Sachs, Bain & Company, and Morgan Stanley.
'Melissa brings the vision, energy, and financial firepower we need as we prepare for the launch of BRIMOCHOL™ PF into global markets,' said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. 'Her deep capital markets experience and strong operational command will be a tremendous asset as Tenpoint grows into a commercial-stage company.'
Epperly currently serves on the boards and audit committees of two Nasdaq-listed biotech companies, including Roivant Sciences and Nautilus Biotechnology. She holds an MBA from Harvard Business School and a BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.
'It's an honor to join Tenpoint at such a defining moment,' said Epperly. 'With breakthrough science, bold goals, and a clear vision for impact, this team is poised to do something extraordinary. I'm eager to help shape what's ahead as we advance BRIMOCHOL™ PF and build toward lasting growth.'
About Tenpoint Therapeutics
Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL PF and has submitted an NDA to the US FDA. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, AlbionVC, British Business Bank (formerly British Patient Capital), Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and Wille AG. To learn more, visit tenpointtherapeutics.com and connect on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Fortinet (FTNT) Launches New AI-Powered Workspace Security Suite and Powerful FortiDLP Upgrades
We recently published a list of . In this article, we are going to take a look at where Fortinet, Inc. (NASDAQ:FTNT) stands against other buzzing AI stocks on latest news and ratings. On June 4th, Fortinet, Inc. (NASDAQ:FTNT) announced a new AI-powered Workspace Security Suite, the FortiMail Workspace Security, along with powerful FortiDLP upgrades, aiming to better protect modern businesses. The new capabilities allow FortiMail to be recognized as one of the broadest and most customizable email security platforms, protecting beyond email to incorporate browser and collaboration security. Together with new features in FortiDLP, Fortinet's next-generation data loss prevention (DLP) and insider risk management solution, users will be able to avail a unified, AI-powered approach to safeguarding users and sensitive data across today's dynamic work environments. A close-up of a user authenticating into a secure network using a two-factor authentication process. By integrating artificial intelligence with integrated email, browser, collaboration, and data security, the company aims to offer better protection for security teams so that they can turn complexity into clarity and threats into easier tasks handled. 'In today's evolving threat landscape, securing user productivity and sensitive data requires a unified strategy that considers both outsider threats and insider risks. Cybercriminals are aiming their efforts right at users and increasingly leveraging tools like FraudGPT, BlackmailerV3, and ElevenLabs to automate the creation of malware, deepfake videos, phishing websites, and synthetic voices—making attacks more scalable, convincing, and difficult to detect. With our expanded AI-powered FortiMail Workspace Security suite and FortiDLP solutions, Fortinet empowers organizations to stay ahead of threat actors and insider risks while ensuring users, data, and productivity remain secure.' Fortinet, Inc. (NASDAQ:FTNT), a cybersecurity company, provides enterprise-level next-generation firewalls and network security solutions, leveraging artificial intelligence across its cybersecurity products. Overall, FTNT ranks 9th on our list of buzzing AI stocks on latest news and ratings. While we acknowledge the potential of FTNT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
26 minutes ago
- Business Wire
FTRE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Fortrea Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP Fortrea class action lawsuit. Captioned Deslande v. Fortrea Holdings Inc., No. 25-cv-04630 (S.D.N.Y.), the Fortrea class action lawsuit charges Fortrea and certain of Fortrea's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Fortrea class action lawsuit, please provide your information here: CASE ALLEGATIONS: Fortrea is a global clinical research organization ('CRO') that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. According to the complaint, in June 2023, Labcorp Holdings Inc. spun off Fortrea as a standalone, publicly traded company (the 'Spin-Off'). At the time of the Spin-Off, certain of the long-term projects in Fortrea's portfolio remained ongoing (the 'Pre-Spin Projects'). In connection with the Spin-Off, Labcorp and Fortrea entered into several transition services agreements (the 'TSAs'), pursuant to which Fortrea pays Labcorp to provide certain transitional services for a set period. The Fortrea class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to Fortrea's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, Fortrea's previously announced EBITDA targets for 2025 were inflated; and (iv) accordingly, the viability of Fortrea's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated. The Fortrea class action lawsuit further alleges that on September 25, 2024, Jefferies published a report downgrading Fortrea from buy to hold, citing perceived weaknesses in Fortrea's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are '[n]ot as [m]aterial as [o]ne [m]ight [t]hink,' stating that 'IT infrastructure costs to exit the TSAs are already non-GAAPed out of adjusted EBITDA. Thus, once TSAs are exited, [Fortrea] will just be replacing TSA costs with internal operating costs.' On this news, the price of Fortrea stock fell more than 12%, according to the complaint. Then, on December 6, 2024, market analyst Baird Equity Research downgraded Fortrea to neutral from outperform after Fortrea abruptly cancelled two scheduled conferences, stating that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell),' according to the complaint. The Fortrea class action lawsuit alleges that on this news, the price of Fortrea stock fell more than 8%. Finally, on March 3, 2025, the Fortrea class action lawsuit further alleges that Fortrea announced its fourth quarter and full year 2024 financial results, disclosing that its 'targeted revenue and adjusted EBITDA trajectories for 2025 [were] not in line with [its] prior expectations.' According to the complaint, specifically, in an earnings call held that same day, Fortrea revealed that Fortrea's Pre-Spin projects are 'late in their life cycle [and] have less revenue and less profitability than expected for 2025,' that 'post-spin work is not coming on fast enough to offset the pre-spin contract economics,' and that 'older versus newer mix issue will continue to negatively impact [Fortrea's] financial performance during 2025.' On this news, the price of Fortrea stock fell more than 25%, according to the Fortrea class action lawsuit. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Fortrea securities during the Class Period to seek appointment as lead plaintiff in the Fortrea class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Fortrea class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Fortrea class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Fortrea class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
37 minutes ago
- Yahoo
NVIDIA Blackwell Fuels AI Surge -- Super Micro Emerges as Top Winner
June 6 - Super Micro Computer (NASDAQ:SMCI) is poised to gain as NVIDIA's (NASDAQ:NVDA) Blackwell GPU rollout accelerates. Analysts point to a $20 billion partnership with Saudi data center firm DataVolt and upbeat upgrades as key drivers. Warning! GuruFocus has detected 5 Warning Signs with SMCI. Last week, NVIDIA reported that Blackwell chips now account for about 70% of its data center revenue, with sales roughly doubling quarter over quarter. These GPUs power cutting-edge AI workloads, and Super Micro's server designs are built to match that demand. SMCI's modular systems feature advanced cooling and power management, making them an ideal match for Blackwell's dense computing requirements. The companies collaborate closely on software integration, ensuring SMCI servers support the latest NVIDIA architectures from day one. Additionally, SMCI's partnership with Saudi data center operator DataVolt, valued at $20 billion, underscores its role in supplying high-density GPU servers. As Blackwell deployments spread across hyperscale facilities, SMCI stands to benefit from strong demand for customizable, high-performance infrastructure. While SMCI's profit margins remain tighter than some peers, its agility in aligning with NVIDIA's AI roadmap helps drive growth. Investors monitoring AI hardware trends view SMCI as a key beneficiary of NVIDIA's expanding GPU ecosystem. Based on the one year price targets offered by 15 analysts, the average target price for Super Micro Computer Inc is $40.00 with a high estimate of $70.00 and a low estimate of $15.00. The average target implies a downside of -1.90% from the current price of $40.77. Based on GuruFocus estimates, the estimated GF Value for Super Micro Computer Inc in one year is $68.35, suggesting a upside of +67.65% from the current price of $40.77. This article first appeared on GuruFocus.
